Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fusion Pharmaceuticals Inc.
Headquarters: Hamilton, ON, Canada
Website: N/A
Year Founded: 2014
Status: Acquired
BioCentury | Feb 4, 2025
Finance
Australian radiopharma play Advancell taps VCs for $112M in ‘scale capital’
Expanding in U.S., the biotech will build manufacturing capacity for α-emitters, including clinical program for prostate cancer
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Sep 17, 2024
Finance
Why radiopharma Pentixapharm chose Frankfurt for IPO
Eckert & Ziegler spinout aiming for 4Q24 debut with secondary listing as future option
BioCentury | Jul 22, 2024
Product Development
Battle of the alphas: lead-212 picks up speed in radiopharma
The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale
BioCentury | Jul 20, 2024
Product Development
Susan Galbraith: Five trends will drive the future of cancer treatment
Part 2 of an interview with AstraZeneca’s head of oncology
BioCentury | Jun 12, 2024
Management Tracks
Former Fusion CFO Crowley joins Centessa
Weinhoff becomes CBO. Plus: QurAlis pads C-suite and updates from PepGen, C4 and more
BioCentury | May 2, 2024
Deals
Novartis gains α-emitter, radioligand platform via $1B Mariana takeout
Largest upfront M&A payment for a preclinical biotech in three years
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Mar 26, 2024
Deals
Deals Report: Week’s M&A includes AZ-Fusion, Novo Nordisk-Cardior
Plus: Intellia deciding to step back from co-developing Factor-IX therapy with Regeneron and GSK returns Sosei’s GPR35 agonist after deprioritization
BioCentury | Mar 21, 2024
Data Byte
Radiopharmaceuticals could soon get their first blockbuster
Pluvicto’s steep launch appears on track to surpass $1B in sales this year
Items per page:
1 - 10 of 44